Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies

References

• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20(7):838–12. doi:10.1016/j.drudis.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Dickopf S, Georges GJ, Brinkmann U. Format and geometries matter: structure-based design defines the functionality of bispecific antibodies. Comput Struct Biotechnol J. 2020;18:1221–27. doi:10.1016/j.csbj.2020.05.006
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. doi:10.1038/s41573-019-0028-1.
   PubMed Web of Science ®Google Scholar
• Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, Huang Y, Xu Y, Qian C. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616. doi:10.3389/fimmu.2021.626616
   PubMed Web of Science ®Google Scholar
• Esfandiari A, Cassidy S, Webster RM. Bispecific antibodies in oncology. Nat Rev Drug Discov. 2022;21(6):411–12. doi:10.1038/d41573-022-00040-2.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs. 2022;14(1):2014296. doi:10.1080/19420862.2021.2014296.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Croy JE, Schirtzinger L, Torgerson S, Breyer M, Wroblewski VJ. Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys. MAbs. 2016;8(5):969–82. doi:10.1080/19420862.2016.1178435.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Brown R, Key S, Cain P, Feng Y. Pharmacokinetic developability and disposition profiles of bispecific antibodies: a case study with two molecules. Antibodies. 2021;11(1):2. doi:10.3390/antib11010002.
   Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25. doi:10.1038/nri2155.
   PubMed Web of Science ®Google Scholar
• Kuo TT, Aveson VG. Neonatal fc receptor and IgG-based therapeutics. MAbs. 2011;3(5):422–30. doi:10.4161/mabs.3.5.16983.
   PubMed Web of Science ®Google Scholar
• Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K. et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs. 2015;7(2):331–43. doi:10.1080/19420862.2015.1008353.
   PubMed Web of Science ®Google Scholar
• Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal fc receptor with fc. Nature. 1994;372(6504):379–83. doi:10.1038/372379a0.
   PubMed Web of Science ®Google Scholar
• Kim J, Firan M, Radu CG, Kim C, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I‐related receptor, FcRn. Eur J Immunol. 1999;29(9):2819–25. doi:10.1002/(SICI)1521-4141(199909)29:09<2819:AID-IMMU2819>3.0.CO;2-6.
   PubMed Web of Science ®Google Scholar
• Jensen PF, Larraillet V, Schlothauer T, Kettenberger H, Hilger M, Rand KD. Investigating the interaction between the neonatal fc receptor and monoclonal antibody variants by Hydrogen/Deuterium exchange Mass Spectrometry*. Mol Cell Proteom. 2015;14(1):148–61. doi:10.1074/mcp.M114.042044.
   PubMed Web of Science ®Google Scholar
• Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC. et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10(2):244–55. doi:10.1080/19420862.2017.1417718.
   PubMed Web of Science ®Google Scholar
• Fernández-Quintero ML, Ljungars A, Waibl F, Greiff V, Andersen JT, Gjølberg TT, Jenkins TP, Voldborg BG, Grav LM, Kumar S. et al. Assessing developability early in the discovery process for novel biologics. MAbs. 2023;15(1):2171248. doi:10.1080/19420862.2023.2171248.
   PubMed Web of Science ®Google Scholar
• Hu S, Datta-Mannan A, D’Argenio DZ. Physiologically based modeling to predict monoclonal antibody pharmacokinetics in humans from in vitro physiochemical properties. MAbs. 2022;14(1):2056944. doi:10.1080/19420862.2022.2056944.
   PubMed Web of Science ®Google Scholar
• Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H. Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci. 2015;104(6):1885–98. doi:10.1002/jps.24430.
   PubMed Web of Science ®Google Scholar
• Piche-Nicholas NM, Avery LB, King AC, Kavosi M, Wang M, O’Hara DM, Tchistiakova L, Katragadda M. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. MAbs. 2018;10:81–94. doi:10.1080/19420862.2017.1389355
   PubMed Web of Science ®Google Scholar
• Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015;112(19):5997–6002. doi:10.1073/pnas.1408766112.
   PubMed Web of Science ®Google Scholar
• Kraft TE, Richter WF, Emrich T, Knaupp A, Schuster M, Wolfert A, Kettenberger H. Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis. MAbs. 2020;12(1):1683432. doi:10.1080/19420862.2019.1683432.
   PubMed Web of Science ®Google Scholar
• Li B, Tesar D, Boswell CA, Cahaya HS, Wong A, Zhang J, Meng YG, Eigenbrot C, Pantua H, Diao J. et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs. 2014;6(5):1255–64. doi:10.4161/mabs.29809.
   PubMed Web of Science ®Google Scholar
• Venkataramani S, Low S, Weigle B, Dutcher D, Jerath K, Menzenski M, Frego L, Truncali K, Gupta P, Kroe-Barrett R. et al. Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies. Biochem Biophys Res Commun. 2018;504(1):19–24. doi:10.1016/j.bbrc.2018.08.064.
   PubMed Web of Science ®Google Scholar
• Wilkinson I, Hale G. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. MAbs. 2022;14(1):2123299. doi:10.1080/19420862.2022.2123299.
   PubMed Web of Science ®Google Scholar
• Müller T, Tasser C, Tesar M, Fucek I, Schniegler-Mattox U, Koch J, Ellwanger K. Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method. MAbs. 2023;15(1):2245519. doi:10.1080/19420862.2023.2245519.
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J. et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. MAbs. 2013;5(4):576–86. doi:10.4161/mabs.24981.
   PubMed Web of Science ®Google Scholar
• Ewert S, Huber T, Honegger A, Plückthun A. Biophysical Properties of Human Antibody Variable Domains. J Mol Biol. 2003;325(3):531–53. doi:10.1016/S0022-2836(02)01237-8.
   PubMed Web of Science ®Google Scholar
• Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of Protein Pharmaceuticals: an update. Pharm Res. 2010;27(4):544–75. doi:10.1007/s11095-009-0045-6.
   PubMed Web of Science ®Google Scholar
• Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8(3):E501–7. doi:10.1208/aapsj080359.
   PubMed Web of Science ®Google Scholar
• Grinshpun B, Thorsteinson N, Pereira JN, Rippmann F, Nannemann D, Sood VD, Nanfack YF. Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies. MAbs. 2021;13(1):1932230. doi:10.1080/19420862.2021.1932230.
   PubMed Web of Science ®Google Scholar
• Raybould MIJ, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis AP, Bujotzek A, Shi J, Deane CM. Five computational developability guidelines for therapeutic antibody profiling. Proc Natl Acad Sci U S A. 2019;116(10):4025–30. doi:10.1073/pnas.1810576116.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I. et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A. 2014;111(52):18601–06. doi:10.1073/pnas.1421779112.
   PubMed Web of Science ®Google Scholar
• Ahmed L, Gupta P, Martin KP, Scheer JM, Nixon AE, Kumar S. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics. Proc National Acad Sci. 2021;118(37):e2020577118. doi:10.1073/pnas.2020577118.
   PubMed Web of Science ®Google Scholar
• Licari G, Martin KP, Crames M, Mozdzierz J, Marlow MS, Karow-Zwick AR, Kumar S, Bauer J. Embedding dynamics in intrinsic physicochemical profiles of market-stage antibody-based biotherapeutics. Mol Pharm. 2022;20(2):1096–111. doi:10.1021/acs.molpharmaceut.2c00838.
   PubMedGoogle Scholar
• Austerberry JI, Dajani R, Panova S, Roberts D, Golovanov AP, Pluen A, van der Walle CF, Uddin S, Warwicker J, Derrick JP. et al. The effect of charge mutations on the stability and aggregation of a human single chain fv fragment. Eur J Pharm Biopharm. 2017;115:18–30. doi:10.1016/j.ejpb.2017.01.019
   PubMed Web of Science ®Google Scholar
• Liu Y, Tsang K, Mays M, Hansen G, Chiecko J, Crames M, Wei Y, Zhou W, Fredrick C, Hu J. et al. An adapted consensus protein design strategy for identifying globally optimal biotherapeutics. MAbs. 2022;14(1):2073632. doi:10.1080/19420862.2022.2073632.
   PubMed Web of Science ®Google Scholar
• Jetha A, Thorsteinson N, Jmeian Y, Jeganathan A, Giblin P, Fransson J. Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies. MAbs. 2018;10(6):890–900. doi:10.1080/19420862.2018.1475871.
   PubMed Web of Science ®Google Scholar
• Liu S, Verma A, Kettenberger H, Richter WF, Shah DK. Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies. MAbs. 2021;13(1):1993769. doi:10.1080/19420862.2021.1993769.
   PubMed Web of Science ®Google Scholar
• Phillips JC, Hardy DJ, Maia JDC, Stone JE, Ribeiro JV, Bernardi RC, Buch R, Fiorin G, Hénin J, Jiang W. et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD. J Chem Phys. 2020;153(4):044130. doi:10.1063/5.0014475.
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Damschroder MM, Cook KE, Li Q, Gao C, Wu H, Dall’acqua WF. Structural insights into Neonatal Fc Receptor-based Recycling Mechanisms. J Biol Chem. 2014;289(11):7812–24. doi:10.1074/jbc.M113.537563.
   PubMed Web of Science ®Google Scholar
• Fiser A, Do RKG, Šali A. Modeling of loops in protein structures. Protein Sci. 2000;9(9):1753–73. doi:10.1110/ps.9.9.1753.
   PubMed Web of Science ®Google Scholar
• Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, Šali A. comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct. 2000;29(1):291–325. doi:10.1146/annurev.biophys.29.1.291.
   PubMedGoogle Scholar
• Robustelli P, Piana S, Shaw DE. Developing a molecular dynamics force field for both folded and disordered protein states. Proc Natl Acad Sci U S A. 2018;115(21):E4758–66. doi:10.1073/pnas.1800690115.
   PubMed Web of Science ®Google Scholar
• Allouche A. Gabedit—A graphical user interface for computational chemistry softwares. J Comput Chem. 2011;32(1):174–82. doi:10.1002/jcc.21600.
   PubMed Web of Science ®Google Scholar
• Jo S, Kim T, Iyer VG, Im W. CHARMM‐GUI: a web‐based graphical user interface for CHARMM. J Comput Chem. 2008;29(11):1859–65. doi:10.1002/jcc.20945.
   PubMed Web of Science ®Google Scholar
• Huang J, Rauscher S, Nawrocki G, Ran T, Feig M, de Groot BL, Grubmüller H, MacKerell AD. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat Methods. 2017;14(1):71–73. doi:10.1038/nmeth.4067.
   PubMed Web of Science ®Google Scholar
• Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. J Chem Phys. 2007;126(1):014101. doi:10.1063/1.2408420.
   PubMed Web of Science ®Google Scholar
• Bernetti M, Bussi G. Pressure control using stochastic cell rescaling. J Chem Phys. 2020;153(11):114107. doi:10.1063/5.0020514.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Kollman PA. Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J Comput Chem. 1992;13(8):952–62. doi:10.1002/jcc.540130805.
   Web of Science ®Google Scholar
• Páll S, Hess B. A flexible algorithm for calculating pair interactions on SIMD architectures. Comput Phys Commun. 2013;184(12):2641–50. doi:10.1016/j.cpc.2013.06.003.
   Web of Science ®Google Scholar
• Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A smooth particle mesh Ewald method. J Chem Phys. 1995;103(19):8577–93. doi:10.1063/1.470117.
   Web of Science ®Google Scholar